2026-10-14T03:53:27Z https://data.mendeley.com/oai

oai:data.mendeley.com/62224ppy2z.1 2025-12-30T08:41:48Z

Ma, Fei Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA) : long-term survival results from the randomized phase 3 PHILA trial Mendeley Data This database derives from the multicentre, double-blind, randomised, open label phase 3 PHILA trial evaluating pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. The shared database includes patient level analysis datasets (ADSL, ADTTE, ADAE, ADCM, ADSLRS, ADEX), covering anonymised subject identifiers, demographics, baseline disease characteristics, treatment allocation and exposure, tumour response assessments, time-to-event outcomes, adverse events, medical history, concomitant medications and follow-up anti-cancer therapies. HER2-Positive Breast Cancer Tyrosine Kinase Inhibitor Randomized Clinical Trial Yan, Min Li, Wei Ouyang, Quchang Tong, Zhongsheng Teng, Yuee Wang, Yongsheng Wang, Shusen Geng, Cuizhi Luo, Ting Zhong, Jincai Zhang, Qingyuan Liu, Qiang Zeng, Xiaohua Sun, Tao Mo, Qinguo Zhou, Shoubing Li, Peidong Cheng, Jing Wang, Xiaojia Nie, Jianyun Yang, Jin Wu, Xinhong Wang, Xinshuai Li, Huiping Yao, Guangyu Fan, Yang Lin, Jiaman Zhu, Xiaoyu Xu, Binghe Dataset doi:10.17632/62224ppy2z.1 oai:data.mendeley.com/62224ppy2z.1 Creative Commons Attribution 4.0 International http://creativecommons.org/licenses/by/4.0 https://data.mendeley.com/datasets/62224ppy2z 2025-12-30T08:41:48Z